Gel for inducing formation of subcutaneous three-level lymph nodes and application of gel in tumor treatment
By encapsulating the chemokine CCL21 in a gel and modifying it with CD40L activating peptide, a porous gel was constructed, which solved the problem of limited activation of immune cells in the tumor microenvironment and enabled the formation of tumor-specific tertiary lymph nodes and the enhancement of anti-tumor immune responses.
Patent Information
- Application Number
- CN202610207835.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-12
- Publication Date
- 2026-05-15
AI Technical Summary
Existing technologies have difficulty effectively inducing the formation of subcutaneous tertiary lymph nodes in the tumor microenvironment, which leads to limited activation of immune cells and affects the efficacy of tumor treatment.
By encapsulating the chemokine CCL21 in the gel and modifying it with CD40L activating peptide, a cryopolymerized porous gel was constructed, which induced the migration of peripheral blood immune cells into the tumor and formed tumor-specific tertiary lymph nodes under the tumor, thereby promoting the activation of immune cells.
It significantly forms T-zone and B-zone, generates tumor-specific immune cells, enhances anti-tumor immune response, and strengthens treatment efficacy.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of tumor treatment technology, specifically to a gel that induces the formation of subcutaneous tertiary lymph nodes and its use in tumor treatment. Background Technology
[0002] The formation of tumor-associated tertiary lymph nodes (TLS) is closely related to a good prognosis in cancer treatment. These structures serve as immune response centers, where extensive antigen presentation, immune cell proliferation and activation occur. Through the formation of T and B zones, highly specific and cytotoxic T and B cells are generated, thereby inhibiting tumor growth. Current methods utilize stromal cells and induce inflammation to promote the formation of natural intratumoral TLS. However, these TLS-based therapeutic strategies are significantly inhibited by the tumor microenvironment. For example, a dense microenvironment inhibits the tumor infiltration of initial immune cells, while an immunosuppressive microenvironment limits cell activation within the TLS. Therefore, overcoming the inhibitory effect of the tumor microenvironment on TLS formation is crucial. Summary of the Invention
[0003] This invention aims to at least partially address one of the technical problems in related technologies. To this end, one objective of this invention is to provide a gel that induces the formation of subcutaneous tertiary lymph nodes, which encapsulates the chemokine CCL21 and modifies the gel surface with an activating peptide derived from CD40L. CCL21 induces the migration of naive T cells and B cells from peripheral blood into the gel, and simultaneously induces the migration of antigen-presenting cells carrying tumor antigens, thereby ensuring that the subcutaneously formed TLS is tumor-specific. Under the activation of CD40Lp, various immune cells interact to form T zones and B zones, ultimately generating tumor-specific immune cells and promoting anti-tumor immune responses.
[0004] A first aspect of this invention provides a gel capable of inducing the formation of subcutaneous tertiary lymph nodes. According to embodiments of the invention, the gel internally encapsulates the chemokine CCL21 and is modified with an activating peptide derived from CD40L.
[0005] Current TLS-related therapeutic strategies all aim to promote the formation of natural intratumoral TLS, but the immunosuppressive microenvironment within tumors severely limits the therapeutic efficiency of these therapies. To address these shortcomings, the inventors induced the formation of TLS subcutaneously in the tumor (scTLS). By encapsulating chemokines, they induced the migration of naïve immune cells and antigen-presenting cells carrying tumor antigens. Simultaneously, by modifying activating peptides, they ensured that the in vitro-formed TLS was in an inflammatory environment, facilitating the activation of immune cells. Through intercellular interactions, significant T-zone and B-zone formation was observed within the in vitro-induced TLS, and subsequent anti-tumor immune responses were efficiently induced.
[0006] Specifically, the inventors constructed a gel with a perforated macroporous structure using freeze polymerization and encapsulated the chemokine CCL21 within it. The gel surface was further modified with the CD40L-derived activating peptide CD40Lp. CCL21 induces the migration of naive T cells and B cells from peripheral blood into the gel, while simultaneously inducing the migration of antigen-presenting cells carrying tumor antigens, thus ensuring that the subcutaneous TLS is tumor-specific. Under the activation of CD40Lp, various immune cells interact to form T-zones and B-zones, ultimately generating tumor-specific immune cells and promoting anti-tumor immune responses. This strategy has not yet been validated in multiple tumor models, providing a new direction for TLS-based therapeutic strategies.
[0007] According to an embodiment of the present invention, the amino acid sequence of the activated peptide derived from CD40L is as shown in SEQ ID NO: 1 or has at least 80% identity with the amino acid sequence shown in SEQ ID NO: 1.
[0008] The amino acid sequence shown in SEQ ID NO: 1 is as follows:
[0009] ATYSEFPGNLKPC.
[0010] When the amino acid sequence of the CD40L-derived activating peptide modified by the gel described in this invention is as shown in SEQ ID NO: 1, it can further activate various immune cells, form T zone and B zone, and ultimately generate tumor-specific immune cells, promoting anti-tumor immune response.
[0011] According to an embodiment of the present invention, the core matrix material of the gel is a polysaccharide or a modified polysaccharide.
[0012] Using polysaccharides or modified polysaccharides as the core matrix material of the gel, it has biocompatibility, water retention and biodegradability, making it an excellent drug carrier.
[0013] According to an embodiment of the present invention, the polysaccharide is hyaluronic acid.
[0014] According to an embodiment of the present invention, the modifying group in the modified polysaccharide is methacrylate.
[0015] According to an embodiment of the present invention, the core matrix material of the gel is hyaluronic acid modified with methacrylate. Hyaluronic acid has high biocompatibility and can further induce lymphatic endothelial cell adhesion, promoting the formation of tertiary lymph nodes.
[0016] According to an embodiment of the present invention, the cross-linking of the gel is a chemical cross-linking through covalent bonds.
[0017] The gel is produced by freeze polymerization, which ensures its porous structure and facilitates cell migration.
[0018] According to an embodiment of the present invention, based on 5 mm 5 mm In a 2 mm volume gel, the chemokine CCL21 is 150-300 ng; According to an embodiment of the present invention, based on 5 mm 5 mm The activated peptide derived from CD40L is 0.1-0.5 mg in a 2 mm gel volume.
[0019] A second aspect of the present invention provides a pharmaceutical composition. According to embodiments of the present invention, the pharmaceutical composition comprises the gel described in the first aspect, capable of inducing the formation of subcutaneous tertiary lymph nodes.
[0020] A third aspect of the present invention provides a drug combination. According to an embodiment of the present invention, the drug combination includes the gel described in the first aspect capable of inducing the formation of subcutaneous tertiary lymph nodes, an immune checkpoint inhibitor, and / or a chemotherapy drug.
[0021] The inventors discovered that combining the gel provided by this invention, which can induce the formation of subcutaneous tertiary lymph nodes, with immune checkpoint inhibitors and / or chemotherapy drug abuse can further enhance the therapeutic effect of scTLS, increase immune cell infiltration, enhance anti-tumor immune response, and improve the survival rate and treatment effect of cancer patients.
[0022] According to an embodiment of the present invention, the immune checkpoint inhibitor is an αPD-1 monoclonal antibody.
[0023] According to an embodiment of the present invention, the chemotherapy drug is doxorubicin.
[0024] The fourth aspect of the present invention provides the use of the gel described in the first aspect capable of inducing the formation of subcutaneous tertiary lymph nodes, the pharmaceutical composition described in the second aspect, and the combination of drugs described in the third aspect in the preparation of a medicament for treating tumors.
[0025] According to an embodiment of the present invention, the tumor is melanoma or colon cancer.
[0026] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Attached Figure Description
[0027] The above and / or additional aspects and advantages of the present invention will become apparent and readily understood from the description of the embodiments taken in conjunction with the following drawings, in which: Figure 1The flow cytometry results used to evaluate the recruitment effect of the gel encapsulating CCL21 on various immune cells are shown. Figure 2 The results of flow cytometry used to evaluate the immune cell recruitment and activation of scTLS in tumor-bearing mice are shown. Figure 3 The results of flow cytometry used to evaluate the specific immune responses induced by scTLS in various tumor model mice are shown. A. Flow cytometry results of OVAp-specific DC cells in scTLS of B16-OVA tumor-bearing mice; B. Flow cytometry results of OVAp-specific T cells in scTLS of B16-OVA tumor-bearing mice; C. Flow cytometry results of CD4+ T cells specific to B16-M27 antigen in peripheral blood of B16-MUC1 tumor-bearing mice; D. Flow cytometry results of CD8+ T cells specific to Adpgk antigen in peripheral blood of MC38 tumor-bearing mice. Figure 4 The results of scTLS treatment on B16-OVA and MC38 tumor-bearing mice are shown. In the figure, A is the survival curve and tumor volume of B16-OVA tumor-bearing mice in the treatment group; B is the survival curve and tumor volume of MC38 tumor-bearing mice in the treatment group. Figure 5 The results of the treatment effect of scTLS combined with monoclonal antibody on MC38 tumor-bearing mice are shown in the figure. The left figure shows the modeling and drug administration route, the middle figure shows the tumor volume of the tumor-bearing mice, and the right figure shows the survival curve of the tumor-bearing mice. Figure 6 The flow cytometry results used to evaluate the efficacy of scTLS in combination with DOX are shown. Figure 7 The results of scTLS transparent three-dimensional fluorescence staining imaging are shown. Detailed Implementation
[0028] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.
[0029] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Furthermore, in the description of this invention, unless otherwise stated, "a plurality of" means two or more.
[0030] The endpoints and any values of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of the various ranges, the endpoint values of the various ranges and individual point values, and individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.
[0031] To facilitate understanding of the invention, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains.
[0032] In this document, the terms “comprising” or “including” are open-ended expressions, meaning they include the contents specified in this invention but do not exclude other aspects.
[0033] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.
[0034] According to a specific embodiment of the present invention, the present invention provides a gel capable of inducing the formation of subcutaneous tertiary lymph nodes, wherein the gel encapsulates the chemokine CCL21 and is modified with an activating peptide derived from CD40L.
[0035] According to a specific embodiment of the present invention, the amino acid sequence of the activated peptide derived from CD40L is as shown in SEQ ID NO: 1 or has at least 80% identity with the amino acid sequence shown in SEQ ID NO: 1.
[0036] In this paper, “identity” is used to describe an amino acid sequence or nucleic acid sequence relative to a reference sequence, employing the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN procedure (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research). Foundation, Washington, DC). Numerous algorithms exist for aligning sequences and determining sequence identity, including: the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48: 443; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2: 482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85: 2444; the Smith-Waterman algorithm (Meth. Mol. Biol. 70: 173-187 (1997); and the BLASTP, BLASTN, and BLASTX algorithms (see Altschul et al. (1990) J. Mol. Biol. 215: 403-410). Computer programs utilizing these algorithms are also available, including but not limited to: ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altschul...). See, Meth.Enzym., 266:460-480 (1996); or GAP, BESTFIT, BLASTAltschul, etc., above, FASTA, and TFASTA, available in Genetics Computing Group (GCG) package, version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.
[0037] In this document, "at least 80% identity" means at least 80% similarity to the reference sequence (amino acid sequence shown in SEQ ID NO: 1), which can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%.
[0038] According to a specific embodiment of the present invention, the amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO: 1 has similar biological activity to the CD40L-derived activating peptide shown in SEQ ID NO: 1, namely, activating various immune cells, forming T zone and B zone, and ultimately generating tumor-specific immune cells to promote anti-tumor immune response.
[0039] According to a specific embodiment of the present invention, the core matrix material of the gel includes, but is not limited to, polysaccharides or modified polysaccharides.
[0040] According to a specific embodiment of the present invention, the polysaccharide is hyaluronic acid or other types of polysaccharides, such as sodium alginate, chitosan, or cellulose derivatives. The gel formed with hyaluronic acid as the core matrix material has better biocompatibility, water retention, and biodegradability.
[0041] According to a specific embodiment of the present invention, the modifying group in the modified polysaccharide is methacrylate. Preferably, the modifying group in the modified polysaccharide is methacrylate, thereby enabling efficient polymerization of hyaluronic acid.
[0042] According to a specific embodiment of the present invention, the core matrix material of the gel is hyaluronic acid modified with methacrylate.
[0043] According to a specific embodiment of the present invention, the crosslinking of the gel can be physical crosslinking or chemical crosslinking. Physical crosslinking involves connecting polymer chains through non-covalent physical interactions to form a three-dimensional network, such as through hydrogen bonds, host-guest interactions, hydrophobic interactions, etc. Chemical crosslinking involves connecting polymer chains through covalent bonds or strong ionic bonds to form a permanent three-dimensional network. Such gels are generally more stable, for example, through chemical reactions between functional groups on the polymer chains to form strong covalent bonds or ionic crosslinks.
[0044] According to a preferred embodiment of the present invention, the crosslinking of the gel is a chemical crosslinking via covalent bonds.
[0045] According to a more specific embodiment of the present invention, the gel is cross-linked in the following manner: Covalent bonding of the core matrix material (methacrylate-modified hyaluronic acid) is achieved through free radical induction by crosslinking agents (including ammonium persulfate and N,N,N',N'-tetramethyldiethylamine). According to a specific embodiment of the present invention, based on 5 mm... 5 mm In a 2 mm volume gel, the chemokine CCL21 is 150-300 ng; According to a specific embodiment of the present invention, based on 5 mm 5 mm The activated peptide derived from CD40L is 0.1-0.5 mg in a 2 mm gel volume.
[0046] According to a specific embodiment of the present invention, based on 5 mm 5 mm In a 2 mm gel, the chemokine CCL21 is 150-300 ng; the activated peptide derived from CD40L is 0.1-0.5 mg. For example, based on a 5 mm gel... 5 mm In a 2 mm volume gel, the chemokine CCL21 can be 150 ng, 180 ng, 200 ng, 220 ng, 250 ng, 280 ng, 300 ng, etc.; the activated peptide derived from CD40L can be 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, etc.
[0047] According to a specific embodiment of the present invention, there are no particular limitations on the preparation method of the gel that can induce the formation of subcutaneous tertiary lymph nodes provided by the present invention. All methods known in the art that can encapsulate the chemokine CCL21 inside the gel and modify the surface with an activating peptide derived from CD40L are covered within the scope of protection of the present invention.
[0048] According to a specific embodiment of the present invention, the gel capable of inducing the formation of subcutaneous tertiary lymph nodes is prepared by the following method: Chemokinase CCL21 was mixed with methacrylate-modified hyaluronic acid, and then a crosslinking agent (ammonium persulfate, N,N,N',N'-tetraethylmethyldiamine) was added. The mixture was polymerized overnight at -20°C, resulting in CCL21 encapsulating within the prepared gel. After the CCL21-encapsulated gel was formed, it was first reacted with NH2-PEG3-NH-CO-CH2I in an EDC / NHS environment to convert the exposed carboxyl groups in the gel into iodine. This iodine then reacted with the thiol groups of Cys in CD40Lp, causing the activated molecule CD40Lp to covalently attach to the surface of the CCL21-encapsulated gel.
[0049] According to a specific embodiment of the present invention, the present invention provides a pharmaceutical composition comprising the aforementioned gel capable of inducing the formation of subcutaneous tertiary lymph nodes. It should be noted that when the pharmaceutical composition is prepared into a pharmaceutical formulation, one or more pharmaceutically acceptable excipients may be added as needed. Those skilled in the art can, based on the intended route of administration and formulation, screen suitable excipients and their dosages from the prior art without inventive effort.
[0050] According to a specific embodiment of the present invention, the present invention provides a drug combination, the drug combination comprising the aforementioned gel capable of inducing the formation of subcutaneous tertiary lymph nodes, as well as immune checkpoint inhibitors and / or chemotherapy drugs.
[0051] It should be noted that the immune checkpoint inhibitors mentioned include, but are not limited to, αPD-1 monoclonal antibodies, and can be any immune checkpoint inhibitor known in the art. There are no particular restrictions on the dosage of immune checkpoint inhibitors; the commonly used dose of the drug or a dose appropriately adjusted according to efficacy can be used.
[0052] According to a preferred embodiment of the present invention, the immune checkpoint inhibitor is an αPD-1 monoclonal antibody.
[0053] It should be noted that the chemotherapy drugs mentioned include, but are not limited to, doxorubicin, and can be any chemotherapy drug known in the art. There are no particular restrictions on the dosage of the chemotherapy drugs; the commonly used dosage or a dosage appropriately adjusted according to the therapeutic effect can be used.
[0054] According to a preferred embodiment of the present invention, the chemotherapy drug is doxorubicin.
[0055] According to a specific embodiment of the present invention, the present invention provides the use of the gel described above that can induce the formation of subcutaneous tertiary lymph nodes, the pharmaceutical composition described above, and the combination of the pharmaceuticals described above in the preparation of a medicament for treating tumors.
[0056] It should be noted that although the embodiments of the present invention only exemplarily demonstrate the therapeutic effect of the gel of the present invention on melanoma or colon cancer, it is easy to understand that the CCL21 encapsulated in the gel provided by the present invention can induce the migration of naive T cells and B cells from peripheral blood into the gel, and at the same time induce the migration of antigen-presenting cells carrying antigens in the tumor, thereby ensuring that the TLS formed under the skin is tumor-specific. Under the activation of CD40Lp, various immune cells interact to form T zone and B zone, and finally generate tumor-specific immune cells, promoting anti-tumor immune response. It is not limited to a specific type of cancer, but is universally applicable to all types of cancer and has significant therapeutic effects, providing a new direction for TLS-based treatment strategies.
[0057] According to a specific embodiment of the present invention, the tumor may be, for example, melanoma, colon cancer or other types of cancer.
[0058] According to a preferred embodiment of the present invention, the tumor is melanoma or colon cancer.
[0059] The present disclosure will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be construed as limiting the scope of the disclosure. Where specific techniques or conditions are not specified in the embodiments, they are performed in accordance with the techniques or conditions described in the literature in the art or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.
[0060] Example 1: Chemokines recruit immune cells Chemokine CCL21 was mixed with methacrylate-modified hyaluronic acid, and then crosslinking agents (ammonium persulfate and N,N,N',N'-tetraethylmethyldiamine) were added. The mixture was polymerized overnight at -20°C, resulting in CCL21 being encapsulated in the prepared gel. The CCL21 content in the encapsulated gel was 200 ng / gel, and each gel piece was 5 mm in size. 5 mm 2mm.
[0061] Healthy mice were subcutaneously injected with CCL21+gel (a gel containing CCL21). Seven days later, the gel was removed, cells were extracted by grinding, and the composition and number of cells were analyzed by flow cytometry. Results are as follows: Figure 1 As shown, the gel encapsulating CCL21 effectively recruits various immune cells, including CD45+ leukocytes, CD3+ T cells, CD19+ B cells, and OVAp-MHC I+CD11c+ DC cells that present OVA antigen. Furthermore, this recruitment is also based on CCL21, specifically manifested in a significant increase in CCR7+ immune cells.
[0062] Example 2: Activation of immune cells within scTLS Obtaining tumor-bearing mice: Each mouse was subcutaneously injected with 1.5... 10 5 B16-OVA cells, with tumor size between 50-100 mm 3 After a period of time, the experiment was conducted.
[0063] To obtain CCL21+CD40Lp+ gel: Chemokine CCL21 was mixed with methacrylate-modified hyaluronic acid, and then a crosslinking agent (ammonium persulfate, N,N,N',N'-tetraethylmethyldiamine) was added. The mixture was polymerized overnight at -20°C, resulting in CCL21 being encapsulated in the prepared gel. The CCL21 content in the encapsulated gel was 200 ng / gel (each gel piece was 5 mm in size). 5 mm (2 mm). After the gel encapsulating CCL21 is formed, it is first reacted with NH2-PEG3-NH-CO-CH2I in an EDC / NHS environment to convert the exposed carboxyl groups in the gel into iodine. Subsequently, it reacts with the thiol groups of Cys in CD40Lp, so that the activated molecule CD40Lp is covalently linked to the gel surface encapsulating CCL21. The content of CD40Lp is 0.2 mg / gel.
[0064] To investigate the activation status of immune cells within scTLS, we injected gels (gels internally encapsulated with CCL21 and externally modified with CD40Lp) into each tumor-bearing mouse (one 5 mm gel was injected into each mouse). 5 mm It was removed and analyzed seven days later (2mm). Figure 2 As shown. Among them, CCL21+CD40Lp+ gel is the experimental group scTLS, and the rest are blank controls and controls containing only one component. According to... Figure 2 Flow cytometry results showed a significant increase in CD45+ leukocytes and CD3+ T cells within the scTLS, and these were CCR7+, indicating that the increase was based on CCL21 recruitment. Simultaneously, T cells within the scTLS were in an early activated state (CD69+CD8+), and the migrating dendritic cells could also be activated by modified CD40Lp (CD86+CD11c+).
[0065] Example 3: Tumor-specific immune response induced by scTLS To verify that subcutaneously formed scTLS is tumor-specific, validation was performed in B16-OVA, B16-MUC1, and MC38 tumor-bearing mice (B16-OVA, B16-MUC1, and MC38 tumor-bearing mouse models were constructed by subcutaneous injection of 1.5... 10 5 6.0 B16-MUC1 or B16-OVA cells; or 6.0 10 5 (1 MC38 cells). For B16-OVA tumor-bearing mice, antigen-specific DC cells and T cells within scTLS were measured. Figure 3 China A Figure 3 (B16-MUC1 tumor-bearing mice) When peripheral blood cells were stimulated with the B16-specific neoantigen B16-M27, mice stimulated with scTLS showed a significant immune response. Figure 3 (C). For MC38 tumor-bearing mice, stimulation with the MC38 neoantigen Adpgk was also used, and the long-term immune effect was measured. Similarly, scTLS stimulation of mice showed a significant immune response. Figure 3 (D). Simultaneously, scTLS was verified to significantly inhibit tumor growth in two tumor-bearing mouse models (B16-OVA and MC38 tumor-bearing mice). Figure 4 (A and B in the middle).
[0066] Example 4: Combination therapy further enhances the treatment effect of scTLS To further evaluate the efficacy of scTLS combined with immune checkpoint inhibitors in the MC38 tumor model, a gel was subcutaneously injected into the successfully constructed MC38 tumor model (Day 9), followed by three intraperitoneal injections of αPD-1 monoclonal antibody (Days 11, 13, and 15). The monoclonal antibody dosage was 0.1 mg / mouse. The therapeutic effects of scTLS combined with immune checkpoint inhibitors were statistically analyzed. Figure 5 As shown, the combined administration significantly inhibited tumor volume in mice, significantly increased survival time, and resulted in complete tumor regression in some tumor-bearing mice. Simultaneously, scTLS was also used in combination with the chemotherapy drug DOX (doxorubicin). Figure 6 Flow cytometry results showed that intratumoral injection of DOX (30 μg / animal) significantly increased the number of intragel-presenting DC cells and B cells carrying OVA antigen, while also increasing the expression of MHC II molecules, thus promoting a stronger anti-tumor immune response within the scTLS. There was also a significant increase in CCR7+ CD45+ leukocytes and CD3+ T cells. Surface DOX promoted immune cell infiltration, and the increased number of CD69+CD8+ cells further demonstrated enhanced intragel activation.
[0067] Example 5: scTLS 3D Imaging Seven days after injecting CCL21+CD40Lp+ gel into B16-OVA tumor-bearing mice, the mice were removed and fixed overnight with 4% paraformaldehyde solution. The tissues were then cleared and immunofluorescence stained using the iDISCO and Clarity methods, and 3D imaging was performed using light-panel microscopy. Finally, the distribution of CD3+ T cells, CD19+ B cells, and CD11c+ DC cells within the scTLS was analyzed using tissue clearing technology. It was observed that significant cellular partitioning, namely the formation of T zones and B zones, was observed within the gel, and DC cells mainly clustered near the T and B zones, assisting in the generation of tumor-specific immune cells. Figure 7 ).
[0068] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," "some implementations," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.
[0069] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.
Claims
1. A gel capable of inducing the formation of subcutaneous tertiary lymph nodes, characterized in that, The gel contains the chemokine CCL21 and is modified with an activating peptide derived from CD40L.
2. The gel according to claim 1, characterized in that, The amino acid sequence of the activated peptide derived from CD40L is as shown in SEQ ID NO: 1 or has at least 80% identity with the amino acid sequence shown in SEQ ID NO:
1.
3. The gel according to claim 1, characterized in that, The core matrix material of the gel is a polysaccharide or a modified polysaccharide; Optionally, the polysaccharide is hyaluronic acid; Optionally, the modifying group in the modified polysaccharide is a methacrylate; Optionally, the core matrix material of the gel is hyaluronic acid modified with methacrylate; Optionally, the gel is cross-linked via chemical cross-linking through covalent bonds.
4. The gel according to claim 1, characterized in that, Based on 5 mm 5 mm In a 2 mm volume gel, the chemokine CCL21 is 150-300 ng; Optionally, based on 5 mm 5 mm The activated peptide derived from CD40L is 0.1-0.5 mg in a 2 mm gel volume.
5. A pharmaceutical composition, characterized in that, The gel comprising any one of claims 1-4 capable of inducing the formation of subcutaneous tertiary lymph nodes.
6. A drug combination therapy, characterized in that, The gel, as described in any one of claims 1-4, is capable of inducing the formation of subcutaneous tertiary lymph nodes, as well as immune checkpoint inhibitors and / or chemotherapeutic drugs.
7. The drug combination according to claim 6, characterized in that, The immune checkpoint inhibitor is an αPD-1 monoclonal antibody.
8. The drug combination according to claim 6, characterized in that, The chemotherapy drug is doxorubicin.
9. Use of the gel capable of inducing the formation of subcutaneous tertiary lymph nodes according to any one of claims 1-4, the pharmaceutical composition according to claim 5, and the combination of drugs according to any one of claims 6-8 in the preparation of a medicament for treating tumors.
10. The use according to claim 9, characterized in that, The tumor is either melanoma or colon cancer.
